- Anti-Aging Medical News – Ischemic Cardiomyopathy Patients Treated with Autologous Angiogenic and Cardio-Regenerative Progenitor Cells
This study exemplifies that ACP’s can improve the ejection fraction in patients with severely reduced cardiac function with benefits sustained to six months. – Physician Resources
- Treatment of Patients with Severe Angina Pectoris Treatment of Patients with Severe Angina Pectoris Findings of this study demonstrate that a progenitor cell population can be readily isolated from peripheral blood. It has a high safety profile and significantly improves clinical symptoms in patients with angina pectoris. – Physician Resources
- British Journal of Hematology – Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages
Blood-derived adult stem cells were previously considered impractical for therapeutic use because of their small numbers. However, this study reports the simple and rapid method of SCP generation and the resulting considerable quantities of lineage-specific precursor cells makes it a potential source of autologous treatment for a variety of diseases. – Physician Resources
- European Journal of Heart Failure – A comparison of cell delivery routes
Human angiogenic cell precursors (ACPs), delivered via intra-myocardial or intracoronary injection, engrafted into damaged cardiac tissue and improved cardiac function within 4 weeks through effects on scar morphology and blood vessel formation. – Physician Resources
Tissue regeneration as next-generation therapy for COPD – potential applications
Shunsuke Ohnishi, Noritoshi Nagaya, International Journal of COPD 2008
Growing evidence obtained from basic and translational research on regenerative medicine in COPD suggests that administration of humoral factors responsible for activation of endogenous stem/progenitor cells or administration of exogenous stem/progenitor cells may be a potential therapeutic tool in the treatment of COPD.
Challenges in the Development of Autologous Cell Therapy Products
Yael Porat, Danny Belkin, Adina Belleli, Jacov Elkayam, Daphna Shimoni, Svetlana Porozov, Ina Sarel, Issar Ash, Valentin Fulga – BioProcessing Journal – Trends and Developments in BioProcess Technology
VesCell is an autologous stem/pro-genitor cellular product composed of non-mobilized, blood-derived cell populations of HSC/progenitor cells and ACP lineage cells. The development of VesCell required an in-depth understanding of the biological characteristics of the product and the establishment of a tightly controlled manufacturing process. The resulting consistent and reliable manufacturing procedure of VesCell enabled its evaluation in preclinical and clinical studies designed to assess its safety and efficacy.
Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages.
Yael Porat, Svetlana Porozov, Danny Belkin, Daphna Shimoni, Yehudit Fisher, Adina Belleli, David Czeiger, William F. Silverman, Michael Belkin, Alexander Battler, Valentin Fulga and Naphtali Savion – British Journal of Haematology 2006
Blood-derived adult stem cells were previously considered impractical for therapeutic use because of their small numbers. However, this study reports the simple and rapid method of SCP generation and the resulting considerable quantities of lineage-specific precursor cells makes it a potential source of autologous treatment for a variety of diseases.
Human angiogenic cell precursors restore function in the infarcted rat heart: A comparison of cell delivery routes-Full
Zhuo Sun, Jun Wu, Hiroko Fujii, Jiang Wu, Shu-Hong Li, Svetlana Porozov, Adina Belleli, Valentin Fulga, Yael Porat, Ren-Ke Li – The European Journal of Heart Failure 2008
The current data suggest that human ACPs generated from peripheral blood may represent a novel therapeutic approach to treat myocardial ischemic disease.
To find out more today, click here or call us at (866) 216-5710.